Newly-Published Colchicine Safety Data Provide First Evidence-Based Dosing ... - Sacramento Bee

Newly-Published Colchicine Safety Data Provide First Evidence-Based Dosing ... Sacramento Bee Colcrys is the only single-ingredient colchicine product to be reviewed and approved by the US Food and Drug Administration, and is indicated for the prophylaxis and treatment of gout flares, and for the treatment of Familial Mediterranean Fever (FMF). ... and more »

Pharmos Corporation Reports 2011 Second Quarter Results - Sacramento Bee

Pharmos Corporation Reports 2011 Second Quarter Results Sacramento Bee Upon successful completion of the preclinical trial, the Company plans to conduct a proof-of concept clinical trial in the US in gout patients using Levotofisopam. This trial follows two ex-US Phase 1 clinical studies that were completed by Vela ... and more »

Ardea Biosciences to Present at Wedbush Securities Life Sciences Conference - Sacramento Bee

Ardea Biosciences to Present at Wedbush Securities Life Sciences Conference Sacramento Bee Lesinurad (RDEA594), our lead product candidate for the chronic management of hyperuricemia in patients with gout, is a once-daily, oral inhibitor of the URAT1 transporter. We have completed Phase 2b clinical studies of lesinurad and continue to ... and more »

Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life ... - Sacramento Bee

Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life ... Sacramento Bee Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. ...